<a href="https://www.fiercebiotech.com/biotech/jj-axes-5b-car-t-dream-months-after-touting-best-disease-efficacy" hreflang="en">J&J axes $5B CAR-T dream months after touting best-in-disease efficacy</a>
Johnson & Johnson has discontinued its CAR-T cell therapy programs, JNJ-9530 and JNJ-4496, which were initially projected to generate over $5 billion in sales, due to changes in portfolio priorities and the evolving treatment landscape for large B-cell lymphoma. This decision comes despite earlier positive clinical data and statements from the company indicating strong efficacy.
For a professional tracking healthtech and biotech, the key insight here is the strategic pivot by Johnson & Johnson in discontinuing its CAR-T cell therapy programs, despite previous high expectations and promising early-phase results. This move highlights the importance of continuously reassessing portfolio priorities in response to evolving treatment landscapes, offering a lesson in the dynamic nature of biotech investments and the potential impacts on related sectors, such as AI-driven drug discovery and precision medicine.